Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pediatrneurol.2020.07.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Description of STRIVE-ON Study Protocol: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Phase III Trial (STRIVE-ON).
Neurocrit Care
January 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Oral nimodipine is the only drug approved in North America for patients with aneurysmal subarachnoid hemorrhage (aSAH). However, bioavailability is variable and frequently poor, leading to fluctuations in peak plasma concentrations that cause dose-limiting hypotension. Furthermore, administration is problematic in patients who cannot swallow.
View Article and Find Full Text PDFCentral retinal artery occlusion following surgery for thyroid eye disease: A case report.
Medicine (Baltimore)
November 2024
Department of Ophthalmology, Mianyang Central Hospital, Mianyang, Sichuan, China.
Rationale: Thyroid eye disease (TED) is the most common orbital disorder in adults and significantly affects patient health. Orbital decompression surgery is an important treatment option. Central retinal artery occlusion (CRAO) after orbital medial wall decompression is rare in patients with TED.
View Article and Find Full Text PDFCerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration.
Clin Pharmacol Ther
February 2025
Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
There is accumulating evidence that cerebrospinal fluid (CSF) concentrations of nimodipine correlate with long-term outcome of patients after subarachnoidal hemorrhage (aSAH) by impeding cerebral ischemia. However, pharmacological data on simultaneous serum vs. CSF and intraparenchymal nimodipine values are rarely reported in larger patient groups.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers used a combination of enteral cilostazol and intravenous high-dose albumin to treat three aSAH patients, leading to a notable improvement in their condition.
- * Post-treatment evaluations showed significant resolution of perfusion issues, vasospasm, and neurological deficits, suggesting that this combination therapy may be effective for severe cases resistant to standard treatments.
Use of dual intraventricular vasodilators for refractory cerebral vasospasm in a pediatric patient with traumatic subarachnoid hemorrhage: A case report.
Am J Health Syst Pharm
December 2024
Emory University Hospital, Atlanta, GA, USA.
Purpose: Subarachnoid hemorrhage (SAH) is a rare but life-threatening clinical event for pediatric patients. Cerebral vasospasm is a common complication of SAH that often leads to poor outcomes. This case report describes the use of dual intraventricular (IVT) vasodilators in a pediatric patient.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!